Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

Abstract We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs <16 mutations/megabase]) in a pan‐tumor population from seven clinical trials. Data sources...

Descrición completa

Detalles Bibliográficos

Principais autores:	Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, David S. Shames, Meghna Das Thakur, Jane Shi, Lorna Bailey, Shweta Vadhavkar, Xian He, Wei Zhang, René Bruno
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2020-12-01
Series:	Pharmacology Research & Perspectives
Assuntos:	atezolizumab biomarkers clinical pharmacology mutation pharmacokinetics tumor
Acceso en liña:	https://doi.org/10.1002/prp2.685
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!